Abstract PO4-13-12: PIK3CA mutational status in tissue & plasma as a prognostic tool in HR+/HER2- breast cancer (BC)
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po4-13-12
Abstract: Background: Activating mutations of PIK3CA gene are described in about 30-40% of BC. They confer overall worse prognosis and resistance to endocrine and chemotherapeutic therapy. Concordance between testing methods (tissue & plasma) are not widely… read more here.
Keywords: mutational status; cancer; tissue plasma; pik3ca mutational ... See more keywords